Member Info for RayPointer

Lindy will know the current situation re whether funding will be required and when.

How close are Scancell to a second Glycans deal and how probable is this?

What are the prospects for further deals beyond this?

How close are Genmab to providing a stage payment?

She was non-comital at the previous AGM but didn't discount the possibility that funding would not be required in 2024.

CW

That's an interesting abstract about targeting glycans for infectious diseases. I wonder if the authors know about Scancell's work on Glycans and Avidimab. It's probably not a line of research that would appeal to Scancell at present but maybe one for the future when Avidimab has more evidence of its effectiveness behind it. I'm thinking, in particular, about the iSCIB1+ cohort results.

Well done in finding that article

I love the banter here but why doesn't anyone talk about the science?

What data?

I suspect, too early for data on Modi1 + CPIs.

For SCIB1, Scancell have released data very recently.

What we may get is a statement on how recruitment is going on the 2 trials.

IMO, the next news items of note will be:

a) iSCIB1+ cohort opened before year end as promised

b) Possible news on the 6 month evaluation by an unnamed company on 1 of the Glycan mAbs. Hopefully with a deal. Although we don't know when the 6 months started unless someone has asked the company.

It may be wrong to assume that news about trial data will be linked to conference attendance and/or AGM. Lindy will release new data when it makes sense from a scientific and/or statistical perspective.

To get remotely near to these SCIB1 + CPIs results with Modi1 + CPIs would be tremendous

On the other hand the plural could refer to the different versions of the Covidity vaccine that were tested pre-clinically, before deciding on the version that was to be used in the South Africa trial.

It struck me as a bit of a conspiracy theory without any supporting evidence

Not surprising with that sort of name

Hi Burble

"Interesting that they mention iSCIB1+ but not Covidity. Unsure what to make of that."

I honestly think this is due to their stated policy to concentrate on Mod11 and SCIB1 currently.

If iSCIB1+ shows great data (and it is looking that way with the initial data from SCIB1) then this may, as a side effect, generate a lot of interest in Avidimab and also Covidity.

It also has the effect of having a long patent life for iSCIB1+.

IMO, it is an astute policy 🤣

Other less optimistic views may exist.

It's better to be holy rather than holey when it comes to cardboard

Drac, there must be a pill to make you happier😂

Cleaner

There are many trials and developments going on for therapies in combination with CPIs. What Scancell are saying is that, to their knowledge, of all the combination therapies for melanoma, the SCIB1 results stand out as being well ahead of the rest.

So the competition is the rest of the field.

Its under "antibodies" cleaner

https://www.scancell.co.uk/seventh-international-cancer-immunotherapy-conference-cicon23-milan-september-2023-1

Well 11 is 73% of 15 so I assume that they were referring to 15 patients but they did not make that clear. I do wonder how many more patients will be dosed with SCIB1 when iSCIB1+ is on the horizon.

Hi Krafty

Just to add a little more detail to Berm's reply.

Proteins comprise chains of amino acids. The two simplest amino acids are arginine and lysine.

Modi1 targets a change to arginine call citrullination.

Similarly, Modi2 targets a change to lysine called h o m o citrullination.

Both changes are classed as Stress Induced Post Translational Modifications (SIPTMs).

The changes can occur on different proteins and at different positions in the proteins. This means that both Modi1 and Modi2 can target different occurrences of the changed amino acids (arginine for Modi1 and lysine for Modi1).

Lindy has also expressed excitement at being able to combine Modi1 and Modi2 which is obviously a few years off.

This excitement tends to indicate that some cancers exhibit both citrullination (Modi1) and h o m o citrullination (Modi2).

Well explained Burble.

That's exactly as I see it.

Exciting times!

I, for one, think both Bermuda and Crumbs are very valuable posters.

I thought she was in a very relaxed mood

Not bad for a bio company with no lab.

More evidence that Lindy is a genius 😀

I think Lindy will want to prove iSCIB1+ before she considers dealing. I think she has already said as much.

Firstly because of the patent situation with SCIB1 and secondly to further improve the results.

Remember her words "If you like SCIB1, you're going to love iSCIB1+"